Literature DB >> 25029937

Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.

Harshad R Kulkarni1, Richard P Baum2.   

Abstract

Neuroendocrine tumors are malignant solid tumors originating from neuroendocrine cells dispersed throughout the body. Differentiated neuroendocrine tumors overexpress somatostatin receptors (SSTRs), which enable the diagnosis using radiolabeled somatostatin analogues. Internalization and retention within the tumor cell are important for peptide receptor radionuclide therapy using the same peptide. The use of the same DOTA-peptide for SSTR PET/CT using (68)Ga and for peptide receptor radionuclide therapy using therapeutic radionuclides like (177)Lu and (90)Y offers a unique theranostic advantage.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ga-68; PRRT; Somatostatin receptors

Mesh：

Substances：

Year:  2014        PMID： 25029937     DOI： 10.1016/j.cpet.2013.08.015

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  11 in total

Review 1.  Recent advances in the preparation and application of multifunctional iron oxide and liposome-based nanosystems for multimodal diagnosis and therapy.

Authors:  Marzia Marciello; Juan Pellico; Irene Fernandez-Barahona; Fernando Herranz; Jesus Ruiz-Cabello; Marco Filice
Journal:  Interface Focus       Date:  2016-12-06       Impact factor: 3.906

Review 2.  Theranostics of Neuroendocrine Tumors.

Authors:  Sze Ting Lee; Harshad R Kulkarni; Aviral Singh; Richard P Baum
Journal:  Visc Med       Date:  2017-10-20

3.  Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.

Authors:  Stefano Severi; Maddalena Sansovini; Annarita Ianniello; Lisa Bodei; Silvia Nicolini; Toni Ibrahim; Valentina Di Iorio; Vincenzo D'Errico; Paola Caroli; Manuela Monti; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-26       Impact factor: 9.236

4.  Impact of 68Ga-DOTA-Peptide PET/CT on the Management of Gastrointestinal Neuroendocrine Tumour (GI-NET): Malaysian National Referral Centre Experience.

Authors:  Teik Hin Tan; Ching Yeen Boey; Boon Nang Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-12-08

5.  Excellence is the Enemy of Good.

Authors:  John Buscombe
Journal:  World J Nucl Med       Date:  2014-09

6.  Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.

Authors:  Sandip Basu; Rohit Ranade; Pradeep Thapa
Journal:  World J Nucl Med       Date:  2016 Jan-Apr

7.  Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.

Authors:  Ken G Andersson; Maryam Oroujeni; Javad Garousi; Bogdan Mitran; Stefan Ståhl; Anna Orlova; John Löfblom; Vladimir Tolmachev
Journal:  Int J Oncol       Date:  2016-10-05       Impact factor: 5.650

8.  Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy.

Authors:  Arturo Loaiza-Bonilla; Paula A Bonilla-Reyes
Journal:  Cureus       Date:  2017-09-24

9.  177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites.

Authors:  Pradeep Thapa; Rahul Parghane; Sandip Basu
Journal:  World J Nucl Med       Date:  2017 Jul-Sep

Review 10.  Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.

Authors:  Imke H Bartelink; Ella F Jones; Sheerin K Shahidi-Latham; Pei Rong Evelyn Lee; Yanan Zheng; Paolo Vicini; Laura van 't Veer; Denise Wolf; Andrei Iagaru; Deanna L Kroetz; Brendan Prideaux; Cornelius Cilliers; Greg M Thurber; Zena Wimana; Geraldine Gebhart
Journal:  Clin Pharmacol Ther       Date:  2018-10-06       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.